Anthropic Adds Novartis CEO Vas Narasimhan to Board as IPO Plans Take Shape

Anthropic has appointed Vas Narasimhan, the CEO of Swiss pharmaceutical giant Novartis, to its board of directors — its second board addition in recent months. The move signals Anthropic's growing ambitions in enterprise healthcare and its preparations for a potential IPO as the AI startup continues to scale.

Who Is Vas Narasimhan?

Vas Narasimhan has led Novartis since 2018, overseeing the company's transformation into a data-driven medicine company with heavy AI investment. Under his leadership, Novartis has used AI for drug discovery, clinical trials, and patient diagnostics. His expertise at the intersection of life sciences and artificial intelligence makes him a strategic fit for Anthropic's board as the company eyes healthcare as a major growth vertical.

Anthropic's Healthcare Push

Anthropic has been investing heavily in making Claude useful for healthcare applications — from clinical decision support to medical research summarization. Adding a sitting pharma CEO to its board gives Anthropic direct insight into the needs and constraints of the healthcare industry, including regulatory hurdles, data privacy requirements, and the pace of enterprise AI adoption in medicine.

IPO Preparations Accelerate

This is Anthropic's second board addition in recent months, a pattern consistent with companies preparing for a public offering. Building out a credible, diverse board is standard pre-IPO housekeeping. With Anthropic valued at over $60 billion following its latest funding round, the company is under increasing pressure from investors to define its public market timeline. Narasimhan's appointment adds financial and governance credibility to that case.

Competition for Healthcare AI Dominance

Anthropic isn't alone in targeting healthcare. OpenAI, Google DeepMind, and Microsoft are all aggressively courting hospitals, insurers, and pharma companies. But Anthropic's safety-first positioning and constitutional AI approach may resonate more strongly in regulated industries where hallucinations and liability risks loom large. Narasimhan's presence on the board could open doors to Novartis and its pharma network as early enterprise customers.

The Bottom Line

Anthropic's appointment of Novartis CEO Vas Narasimhan to its board is a deliberate move that serves two goals: deepening its healthcare strategy and burnishing its governance credentials ahead of a potential IPO. As AI companies compete for dominance in enterprise medicine, having a top pharma executive in the boardroom could prove to be a meaningful differentiator.